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Julius Schachter offers a provocative title
in his expert review of the diagnostic
Chlamydia trachomatis droplet digital
PCR (CT ddPCR) assay developed by
Roberts et al. [1,2]. He put forward four
main objections to the utility of this test
in the face of other next-generation
commercial nucleic acid amplification
test platforms. These objections may be
summarized as follows:
• The CT ddPCR assay is insufficiently
sensitive for use in mass drug adminis-
tration (MDA) treatment programs
for trachoma control;
• The CT ddPCR assay was evaluated
against an inappropriate commercial
reference test (Roche Amplicor CT/NG
test);
• No gold standard was used to evaluate
the CT ddPCR assay;
• The original report failed to document
the processes and procedures that are
required to perform a test on a drop-
let digital PCR platform.
We would like to respond to the
comments as discussed below.
Sensitivity
The sensitivity required of a test for
infection for use by trachoma control
programs is currently unknown. At a
recent (September 2013) meeting at the
London School of Hygiene and Tropical
Medicine, leading trachoma experts were
asked by the Bill and Melinda Gates
Foundation to advise on the use of tests
for ocular infection in trachoma control
programs. It was agreed that a highly
specific (>98%) test was required and
that the main utility would be informing
the decision about when to discontinue
treating districts and communities with
azithromycin (a threshold of 1% positiv-
ity in the target population of 1–9 years
old was recommended). What was
unclear, due to lack of empirical data,
was the level of sensitivity required, but
some experts suggested a minimum sen-
sitivity of 80%. In our evaluation, we
showed how the relaxation of the classi-
fication confidence threshold ‘Zeta’
would have raised our estimated sensitiv-
ity above this value. However, we sug-
gest for the reasons outlined below that
the sensitivity estimates presented in our
evaluation are likely misleading. The
issues behind calculating sensitivity in
ddPCR and the reasons why this
appeared ‘low’ given the technical supe-
riority of digital PCR have been dis-
cussed [1,3]. The low sensitivity that we
reported is most likely explained simply
by sampling error, which is a problem
that is unavoidable at low analyte con-
centrations in any test system [4], as
reported by Schachter et al. in 2006 [5].
In the CT ddPCR assay, we used the
Poisson formula to estimate sample
target concentration. The Poisson for-
mula estimates that with a single
approximately 5 ml aliquot, the lowest
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concentration of targets that can be detected with negligible
(<1%) risk of a failing to sample any target in a given aliquot
is 1 copy per ml. We showed that ddPCR+ Roche Amplicor
CT/NG test- samples had low concentration estimates
(<1 copy per ml, £5 copies per aliquot). The discrepancies
that we observed, therefore, occurred in a mathematically pre-
dictable manner. The Roche Amplicor CT/NG test is not a
quantitative test, so we could not fully investigate whether
ddPCR- Roche Amplicor CT/NG test+ results also occurred
only in low load samples. However, we have tested further ali-
quots of the same specimens with a conventional quantitative
multiplex PCR (qPCR) assay that was based on the same
primer and probe sequences as ddPCR. We found that both
types of discrepant result (ddPCR+qPCR- and ddPCR-qPCR+)
occurred only when the estimated concentration of the target
was £5 copies per aliquot [ROBERTS ET AL., UNPUBLISHED DATA].
The report of specificity and sensitivity in our study was pre-
sented in a standard format and we presented our data at ‘face val-
ue’ without the use of discrepant analysis. The results obtained
using the multiplex qPCR can be used as a test of discrepant arbi-
tration, which results in estimates of CT ddPCR sensitivity
>98%, but this common practice has serious limitations [6]. Our
evaluation could also have ensured a higher estimate of CT
ddPCR sensitivity simply by increasing the template volume,
while maintaining a smaller aliquot in the reference test. How-
ever, we used equivalent amounts of DNA template in each of the
CT ddPCR and Roche Amplicor CT/NG tests, unlike the recent
evaluation of the Cepheid Xpert CT/NG Assay, performed on
the GeneXpert and Abbott RealTime CT/NG assay on the
m2000 platform [7], which used an 8:1 ratio of target input
amounts in the newer tests compared with the reference (Aptima
Combo 2 assay). We do not dispute the high sensitivity of the
Cepheid Xpert CT/NG and Abbott RealTime CT/NG assays, but
suggest that the head-to-head comparisons reflected a comparison
of two differing operating procedures as well as the absolute tech-
nical performance of the assays. Cost, simplified operating proce-
dures and selection of classifier cut-off values that are compatible
with programmatic goals are probably more important criteria on
which to base the selection of a test for use in trachoma control
programs. Some technical improvement can be achieved for these
DNA-based tests by targeting multiple target sequences, which
can enhance sensitivity at low analyte concentrations [8] and this
needs to be explored in the ddPCR system. Indeed, the Abbott
RealTime CT/NG assay targets two CT sequences, which is likely
to increase its sensitivity compared with single target assays; how-
ever, the potential enhancement should only be measured by an
evaluation that compares equivalent aliquot sizes.
Choice of reference test
The reviewer correctly points out that a more accurate estimation
of sensitivity could have been obtained by using a reference test
that targeted RNA, such as the Gen-Probe Aptima Combo
2 (CT/GC) assay. Yet the comparison with the Roche Amplicor
CT/NG test is important because it has historically been the
most widely used method for detecting ocular CT infections in
trachoma research programs and it is therefore desirable to
directly compare CT ddPCR with the Roche Amplicor CT/NG
test. We are, however, in the process of addressing these concerns
by undertaking an assessment of the performance of a modified
version of the CT ddPCR against a commercial RNA-based test.
Standards
Both the CT ddPCR assay and the multiplex PCR CT assays
that we developed were used in the February 2012 external
quality assessment program CTDNA13A organized by quality
control for molecular diagnostics [9]. Both assays reported
100% of core samples correctly. We failed to detect CT or
obtained presumptively positive results with low confidence
(z <0.95) in two samples that were included for ‘educational’
purposes, each of which was estimated to contain £0.07 copies/
ml. This analyte concentration is outside our reported dynamic
range for a single test and in these cases we would have
required larger aliquot sizes or a number of technical replicates
to overcome the effects of sample dispersal and sampling het-
erogeneity. Adherence to the quality control for molecular diag-
nostics protocols required that samples were processed as part
of the laboratory’s normal sample handling workflows, there-
fore, no modifications were made. Of the total datasets
reported by all participants in this external quality assessment
program, 91.2% reported correct results for all core samples
indicating that some 8% of the 244 laboratories (273 data sets)
taking part in the evaluation failed to correctly identify core
proficiency samples. Of these, 2% of laboratories using com-
mercial real-time PCR tests and platforms failed to identify one
or more of the core samples correctly, which was equivalent to
those laboratories using in-house real-time PCR detection
methods. We could conclude, therefore, that the use of com-
mercial reagents and test systems per se does not always guaran-
tee improved performance over in-house developed tests.
Operating procedures
The reviewer questioned the costs and workflow of the ddPCR
platform and suggested that the Abbott RealTime CT/NG
assay on the m2000 platform or the Cepheid Xpert CT/NG
Assay, performed on the GeneXpert would be better platforms
suited for trachoma control programs. There are in fact many
commercial test platforms and options available for CT detec-
tion, just as there are a number of well-evaluated in-house
nucleic acid amplification tests. Some of these tests have been
evaluated for use in trachoma monitoring and we would expect
that many of these options would be fit for purpose. The hard-
ware costs of the commercial platforms and per sample costs
are generally beyond the constrained budgets of most national
eye health programs in resource-poor settings where trachoma
remains endemic. For example, in the six districts of the Kili-
manjaro region of Tanzania (population ~200,000 per district),
only three allocated any annual funds for any care services with
the maximum level of annual support being Tsh 2,000,000
(~US$1750) in a single district [10]. No money was directly
allocated for trachoma control. Attempts to negotiate and
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install ‘gratis’ platforms from the major market leaders in coun-
tries with high trachoma burden have stalled and are yet to
translate into working service centers for trachoma control.
This is despite the success of other programs with access to
hardware and diagnostic technical expertise in African laborato-
ries. For example, the AMPATH laboratories at Moi Univer-
sity, Eldoret, Western Kenya, have access to the Abbott
m2000 platform and meet ISO 15189 and DAIDS standards
[VAN DER POL B, PERS. COMM.]. African centers such as the one at Moi
University could in theory be utilized for CT diagnostics. The
GeneXpert platform is also widely deployed within tuberculosis
research and control programs in multiple centers and represents
a feasible alternative [11,12]. But until the un-met need is resolved,
further options should continue to be explored. Indeed, as
Schachter acknowledged, innovation in the research laboratory
drives discovery and can translate into the clinic, ultimately
resulting in changes to health systems policy. The open publica-
tion of methods, targets, validation and evaluation data is also of
benefit to the scientific, commercial and national health commu-
nities. Current options in the ddPCR market have been reviewed
by others including editorial review by Nature Methods. The
recent publication of guidelines for the reporting of digital PCR
experiments indicates that a previously niche technology is now
rapidly entering the mainstream [13–15].
Regarding the operating procedures for the CT ddPCR
assay, specimens can be stored on dry swabs prior to DNA
extraction. The cost per test including DNA extraction is
approximately £5. The current UK list price of the Bio-Rad
QX200 system is £68,000. Ninety-six samples can be processed
in around 3 h and a single operator can comfortably perform
up to 4 runs of 96 samples per day. CT ddPCR is a multistep
process that requires standard liquid handling and transfers.
The basic steps are DNA extraction, PCR formulation, droplet
generation, thermal cycling and droplet reading. The workflow
is similar and less technically challenging than Roche Amplicor
CT/NG test or a simple ELISA. Data analysis is simple and
can be automated. Very little training is required to become
proficient. Assays require little further optimization when trans-
ferring from existing qPCR platforms.
Concluding remarks
As Schachter pointed out, the greatest advantage of the CT
ddPCR assay is the quantitative capability [2], but secondary to
this is the flexibility in the choice of method used for the DNA
template preparation. This flexibility means that other tests can be
performed on the same specimen, which is crucial for research
programs. Commercial tests frequently lack this flexibility, often
the entirety of the specimen is dedicated to the diagnostic assay
and material can only be interrogated post hoc by preparing tem-
plate from residual material. The DNA obtained from the ocular
specimens that we evaluated in our initial report has also been
used to perform a multiplex CT-qPCR assay, to confirm CT
genome sequencing results and to investigate the influence of CT
plasmid copy number variations on ocular disease severity [16].
ddPCR offers a novel approach to the investigation of how fea-
tures of infection besides bacterial load contribute to transmission,
disease severity and pathogen population genetics. The ability of
the ddPCR technique to identify rare variants in samples contain-
ing a dominant or a majority sequence type will allow precise
investigation of the frequency of mixed genovar CT infections.
The application of ddPCR to the determination of haplotype fre-
quencies can be used to assess recombination. Such applications
of ddPCR are currently dramatically altering the detection and
monitoring of residual disease in cancer and detection of break-
through viral escape mutants following treatment [17–22].
The trachoma community is moving to embrace tests for
infection as a guide to making decisions about delivery of MDA.
The load of bacterial carriage is also important and there is addi-
tional value in the determination of the community ocular
load [23]. Measurement of the community ocular load could be
used to monitor the effectiveness of sustained annual treatment
and further inform the decision to discontinue MDA at a thresh-
old where the ocular CT population is no longer self-sustaining.
There is, therefore, a major role for quantitative tests, of which
ddPCR is one of several next-generation technologies that
improve upon qPCR. We envisage ddPCR will complement,
rather than displace the existing technologies that are currently
used in chlamydial and infectious disease diagnostics.
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